Lipocine Completes Phase 3 Trial for Postpartum Depression

Lipocine ( (LPCN) ) has shared an update.

On February 18, 2026, Lipocine announced that the last patient completed the final visit in its pivotal randomized, double-blind, placebo-controlled Phase 3 trial of LPCN 1154, an oral formulation of brexanolone, for severe postpartum depression. The 90‑patient study, conducted at 19 U.S. sites in an outpatient setting without required medical monitoring, reported a favorable safety profile with only mild to moderate nervous system adverse events and no drug-related serious events or treatment discontinuations.

The trial design closely mirrored prior registrational studies for intravenous brexanolone that supported approval of Zulresso for postpartum depression, including similar patient severity, treatment duration, and primary endpoint measuring change in HAM-D score at Hour 60. Lipocine expects Phase 3 data to support a 505(b)(2) NDA filing for LPCN 1154 in 2026, highlighting the drug’s potential to offer rapid symptom relief, short 48‑hour at‑home dosing, and improved tolerability, which could strengthen the company’s position in the PPD market and address key access and convenience limitations of existing therapies.

The most recent analyst rating on (LPCN) stock is a Hold with a $11.00 price target. To see the full list of analyst forecasts on Lipocine stock, see the LPCN Stock Forecast page.

Spark’s Take on LPCN Stock

According to Spark, TipRanks’ AI Analyst, LPCN is a Neutral.

The score is held back primarily by weak financial performance (losses and persistent cash burn despite $0 debt) and limited valuation support (negative P/E, no dividend). These are partly offset by strong recent technical momentum and positive, catalyst-driven corporate events around Phase 3 progress and favorable safety readouts.

To see Spark’s full report on LPCN stock, click here.

More about Lipocine

Lipocine Inc. is a U.S.-based biopharmaceutical company that leverages a proprietary technology platform to develop innovative orally delivered therapies targeting large markets with significant unmet medical needs. Its pipeline spans candidates for postpartum depression, major depressive disorder, epilepsy, essential tremor, obesity-related body composition, liver cirrhosis symptoms, and preterm birth, and it has an FDA-approved oral testosterone therapy, TLANDO, for male hypogonadism.

As of January 30, 2026, Lipocine reported cash and cash equivalents of approximately $19 million, underscoring its status as a clinical-stage developer balancing multiple programs alongside efforts to secure partnerships. The company’s focus on patient-friendly oral alternatives positions it competitively in markets where existing treatments can be invasive, slow-acting, or poorly tolerated, particularly in neuropsychiatric and endocrine-related indications.

Average Trading Volume: 128,966

Technical Sentiment Signal: Buy

Current Market Cap: $48.08M

See more insights into LPCN stock on TipRanks’ Stock Analysis page.